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Abstract
Major depressive disorder (MDD) is common and costly. Primary care remains a major access
point for depression treatment, yet the successful clinical resolution of depression in primary care
is uncommon. The clinical response to depression suffers from a “treatment cascade”: the affected
individual must access health care, be recognized clinically, initiate treatment, receive adequate
treatment, and respond to treatment. Major gaps currently exist in primary care at each step along
this treatment continuum. We estimate that 12.5% of primary care patients have had MDD in the
past year; of those with MDD, 47% are recognized clinically, 24% receive any treatment, 9%
receive adequate treatment, and 6% achieve remission. Simulations suggest that only by targeting
multiple steps along the depression treatment continuum (e.g. routine screening combined with
collaborative care models to support initiation and maintenance of evidence-based depression
treatment) can overall remission rates for primary care patients be substantially improved.
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Introduction
Major depressive disorder (MDD) is common and costly. Over the course of a year, between
13.1 and 14.2 million people will experience MDD.[1] By 2030, depression itself is
projected to be the single leading cause of overall disease burden in high-income countries.
Worldwide, depression makes a large contribution to the burden of disease, ranking third
worldwide, eighth in low-income countries, and first in middle- and high-income countries.
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[2] In 2000, the U.S. economic burden of depressive disorders was estimated to be $83.1
billion; nearly 1/3 of these costs are attributable to direct medical expenses.[3] Projected
depression-related workforce productivity losses are $24 billion annually.[4]
Primary care remains a major access point for depression treatment. Primary care
practitioners manage approximately one third to one half of non-elderly adults[1,5] and
nearly two thirds of older adults[6] who receive treatment for MDD. The severity of
depressive symptoms in patients receiving treatment in primary care is equivalent to that of
patients treated in psychiatric settings.[7,8] Indeed, the World Health Organization has
identified the “urgent importance” of integrating mental health into primary care as the most
salient means of addressing the global burden of mental health conditions.[9]
Yet, despite advances in depression management that are directly relevant to primary care,
including the availability of a wider range of antidepressants with greater tolerability than
earlier medications[10] and the effectiveness and feasibility of evidence-based
collaborative[11] and measurement-based care strategies[12] in primary care settings, the
successful clinical resolution of depression in primary care practice is uncommon. As with
other chronic illnesses,[13] the clinical response to depression suffers from a “treatment
cascade”: for a depressive disorder to be successfully treated clinically, the affected
individual must enter the health care system, be recognized clinically, initiate treatment,
receive adequate treatment, and respond to treatment. Major gaps currently exist in primary
care at each step along this treatment continuum, with the result that at the population level,
the vast majority of patients with depressive disorders remain untreated or ineffectively
treated.
Our purpose in this paper is to quantify the “depression treatment cascade” – the cumulative
shortfalls in clinical recognition, initiation of treatment, adequacy of treatment, and
treatment response for depressed patients in primary care. We will examine key current
debates relevant to the depression treatment cascade and review options for improving the
population-level treatment of depression in primary care.
The Depression Treatment Cascade
The steps required for successful depression treatment lie along a treatment continuum or
cascade (Figure 1). Here we review the literature regarding the prevalence of depression in
the general population, the proportion of prevalent cases in primary care that are recognized
clinically, the proportion of clinically recognized cases that are treated, the proportion of
treated cases that receive adequate treatment, and the proportion of adequately treated cases
that achieve depression remission.
Prevalence
Estimates of the prevalence of depression vary depending on population, measure, and time
frame. A 2005 study using data from the National Epidemiologic Survey on Alcohol and
Related Conditions, in which face-to-face surveys of >43,000 US adults (age 18+) were
conducted, estimated the 12-month prevalence of major depressive disorder (MDD) as 5.3%
and the lifetime prevalence as 13.2%, using the Alcohol Use Disorder and Associated
Disabilities Interview Schedule–DSM-IV Version (AUDADIS-IV) from the National
Institute on Alcohol Abuse and Alcoholism to identify MDD.[14]The Joint Canada/United
States Survey of Health, which conducted >5,000 telephone interviews of US adults in 2007,
reported a slightly higher 12-month MDD prevalence estimate of 8.7% based on the criteria
of the Diagnostic and Statistical Manual, Fourth Edition (DSM-IV).[15]The National Co-
morbidity Survey Replication (NCS-R), which used the Composite International Diagnostic
Interview (CIDI) depression screener during face-to-face household surveys conducted from
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2001-2002, estimated a 12-month MDD prevalence of 6.6% and lifetime prevalence of
16.2%.[1] However, not all patients with major depression in the general population will
seek medical care. A meta-analysis of 8 US studies of depression in primary care reported a
pooled estimate for current MDD of 12.5% (95% CI: 7.4-18.7%) based on structured gold-
standard assessments.[16]
Clinical recognition
While depression is common among the general population, its clinical recognition is less
common. A recent meta-analysis of 118 studies including over 50,000 patients estimated
that general practitioners correctly identify depression 47% of the time.[17]
Initiation of treatment
When depression is recognized clinically, it often goes untreated indefinitely or for a
prolonged period of time after diagnosis. Data from the National Comorbidity Survey
Replication (NCS-R) that included >9,000 participants, found that the vast majority of
lifetime major depression cases eventually initiate treatment, but that delays in treatment
initiation can be excessive.[18] They projected that 88% of those with lifetime major
depressive episodes (MDE) initiated treatment at some point after onset, but that only 37%
did so within a year of depression onset; median duration of delay was eight years. In a
separate 2005 study using the same NCS-R data, 57% of those with a major depressive
episode (MDE) in the past year used any mental health services during that year.[19]
Adequacy of treatment
Of those receiving “any” mental health treatment, only a subset are likely receiving adequate
treatment. Adequate treatment for psychotherapeutic treatments generally requires at least 8
sessions.[1] For pharmacological management of depression, a core principle involves
regular evaluation of depressive symptom response and side effects, combined with
increasing antidepressant doses if response has not been achieved.[20,21] Further, an
adequate medication trial implies a reasonable dose and duration for the treatment, often
described as at least a moderate dose for at least 6-8 weeks.[22]
Based on NCS-R data for the US general population, 64% of those being treated in the
specialty mental health sector and 41% of those being treated in the general medical sector
receive “adequate” depression treatment. This study defined “adequate depression
treatment” as receiving at least 8 psychotherapy visits or at least 4 medication monitoring
visits in the prior year.[1] This definition is likely to produce a generous estimate of
adequacy of pharmacological treatment, since number of appointments does not indicate
whether doses were adjusted based on the patient’s response to treatment. In the study
mentioned in the previous section, Wang, et al found that of those with past-year MDE who
utilized any services in the past year, the median number of visits was 5.5. They determined
that 38% were receiving “minimally adequate treatment,” which they defined as
pharmacotherapy for at least 2 months plus more than 4 visits to any physician; or at least 8
psychotherapy visits of 30 minutes or more to any provider.[19]
Treatment response
Even among those receiving adequate and closely monitored treatment with psychotherapy
or antidepressants, not all patients achieve full treatment response. In depression treatment,
full response, or remission, is defined as complete resolution of depressive symptoms and a
full return of functioning,[23] usually defined as achieving a score <8 on the standardized
Hamilton Rating Scale for Depression (HRSD). In STAR*D, a study of over 4,000 patients
that defined the relative benefit of different depression treatment strategies for a “real world”
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clinical population with multiple medical and psychiatric comorbidities, approximately one-
third of participants achieved remission after 12 weeks of treatment with a first
antidepressant and approximately two-thirds achieved remission after up to three depression
treatment strategies.[22]
Summary
Based on the above review, we posit the following summary estimates, with 95% Bayesian
credible intervals (BCI),[24] to define the depression treatment cascade (Figure 2). Based on
the heterogeneity of the source data, these summary estimates and BCIs are not formal meta-
analytic pooled estimates but represent our qualitative summary of the central tendency and
uncertainty for each parameter.
• For the prevalence of past-year MDD (p0), weighting most heavily the Mitchell et
al. meta-analysis, we propose a summary estimate of 12.5% with a 95% BCI of
7-19%.
• For the proportion with a clinically recognized diagnosis among all those with a
diagnosis (p1), relying on the large meta-analysis, we propose a summary estimate
of 47% with a relatively narrow 95% BCI of 42-53%.
• For the proportion receiving any treatment among those with a recognized
diagnosis (p2), we propose a summary estimate of 50% with a broader 95% BCI of
33-67%, noting the wider divergence between the reviewed estimates.
• For the proportion receiving adequate treatment among those receiving any
treatment (p3), we propose a summary estimate of 40% with a 95% BCI of 30-50%,
reflecting estimates from general medical settings in the NCS-R, noting that this is
likely to be a generous estimate of adequacy.
• For the proportion achieving remission among those receiving adequate treatment
(p4), we propose a summary estimate of 65% with a 95% BCI of 50-80%,
reflecting the results of the STAR*D trial.
Combining these estimates, we estimate that of all primary care patients with past-year
MDD, 47% (95% BCI: 42-53%) are recognized clinically, 24% (16-34%) are receiving any
treatment, 9% (6-15%) are receiving adequate treatment, and 6% (4-10%) have achieved
remission (Figure 3). In other words, we estimate that 76% of primary care patients with
depression are not receiving any treatment, 91% are not receiving adequate treatment, and
94% have not achieved remission. The methodology of constructing the summary BCIs is
presented in Figure 4.
Improving Population-Level Remission
Figure 3 demonstrates that multiple large gaps impede the effective clinical resolution of
depression in primary care patients. With the combination of low clinical recognition of
depression, failure to initiate depression treatment, inadequate depression treatment, and
depression treatment failure, 15 out of 16 primary care patients with depression continue to
have unresolved depressive symptoms.
Figure 5 illustrates the hypothetical impact of different types of interventions to try to
improve population-level depression remission rates. Interventions singly focused on
increasing clinical recognition through screening (1), increasing treatment initiation (2), and
improving adequacy of treatment (3), with each achieving a hypothetical 80% success rate
in its target indicator, would all modestly increase overall remission rates. Based on the
model, improving adequacy of treatment to 80% would have the largest single impact,
doubling remission rates to 12%. Given that our model reflects a fairly generous definition
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of adequacy, this is likely to be an underestimate of the actual gains achievable by focusing
on improving adequacy. Efforts to develop more efficacious treatments (4) would have
marginal impact on remission rates. However, substantial gains in depression remission rates
could only be achieved by targeting multiple gaps. An intervention that increased clinical
recognition, treatment initiation, and treatment adequacy (1-3) all to 80% would increase
remission rates from 6% to 33%.
Achieving such an improvement on multiple fronts would likely require service delivery
changes in primary care. Such an effort might include routine screening for depression
linked to confirmatory assessments for those with positive depression screens and
collaborative care approaches to ensuring timely initiation and adequacy of depression
treatment. Such collaborative care and algorithmic decision support approaches for
delivering high-quality depression treatment in non-psychiatric settings, including primary
and chronic medical care, have proven both efficacious and effective.[22,25-27]
To screen or not to screen
The preceding analysis suggests that clinical under-recognition of depression presents a
major barrier to improving depression remission rates at the population level. Indeed,
systematic review evidence[28] led the United States Preventive Services Task Force
(USPSTF) in 2009 to recommend screening adults for depression in practices with systems
to ensure accurate diagnosis, effective treatment, and appropriate follow-up.[29] However,
others have argued that there is no evidence that screening per se improves mental health
outcomes for patients and that depression screening programs carry risks that are not
justified by the uncertain benefits.[30] Here we review the arguments that have been put
forward in favor of and against routine depression screening programs in general-population
primary care practices.
In favor
Support for routine depression screening is mainly based on evidence that such screening,
when combined with the proper follow-up care, can improve depression outcomes.
O’Connor, et al addressed the question of whether or not to screen for depression in primary
care by examining evidence for the guidelines used by the USPSTF in making its screening
recommendation.[28] They assessed 1) whether there was evidence that screening reduces
morbidity and/or mortality; 2) the effect of clinician feedback of screening test results on
depression response and remission; and 3) adverse effects of antidepressant treatment for
depression. Several studies have reported that screening programs combined with staff
support in depression care achieve important improvements in depressive symptoms relative
to usual care.[31-38] Antidepressants were found to be tolerated by most patients.[39-46]
O’Connor and colleagues identified no evidence of harm from screening programs, and
concluded that screening programs are effective when staff members other than primary care
providers provide some of the depression care, or when patients are enrolled in specialty
mental health care. They noted, however, that evidence does not show any benefit from
screening programs not linked to treatment.
Against
The majority of arguments against routine screening posit that the benefits gained through
screening do not outweigh its potential harms.[30] For example, Gilbody, et al[47]
conducted a meta-analysis of 11 studies and found no reduction in depression prevalence or
improvement of depressive symptoms due to depression screening. Thombs and
colleagues[30] noted that while the four studies upon which the USPSTF recommendation
was based all found improved outcomes among depressed patients after staff-assisted
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depression management programs, none of them actually evaluated depression screening.
Thombs and colleagues also cited rising rates of antidepressant prescriptions as evidence
that depression is already being adequately diagnosed. Potential disadvantages to screening
include large numbers of false positives,[48,49] with the potential “nocebo” effect of
causing a patient to develop depressive symptoms by labeling him with a false diagnosis,
and the lower efficacy of depression treatment for patients with less severe depression.
[50,51] Thombs and colleagues conclude that there is no clearly demonstrated evidence of
benefit from the resource-intensive process of depression screening, and given the potential
unintended negative effects of screening, it should not be recommended in primary care.
Implications of unresolved depression for chronic medical conditions
The public health importance of improved strategies to successfully treat depression derives
not only from the burden of depression itself, but also from the intersection of depression
with many of the chronic medical conditions of major public health importance. Depression
is over-represented in most chronically ill populations relative to the general population,
including patients with diabetes, cardiovascular disease, chronic kidney disease, and HIV
infection.[52-55] Across these conditions, as with the general primary care patient
population, depression is consistently under-diagnosed and under-treated.[56,57] Also
across these conditions, depression is consistently associated with poorer engagement in
chronic medical care, poorer adherence to chronic medical treatment regimens, and worse
clinical outcomes.[27,58-63] While collaborative care approaches that link mental health
and medical treatment teams have demonstrated some success in improving depressive and
medical outcomes in primary care and comorbid patients,[22,25,27] such approaches are not
yet widespread.
Conclusion
MDD remains an important but challenging management issue in primary care. Reasonably
effective treatments exist, but shortfalls at multiple steps along the treatment delivery
pathway suggest that only 9% of depressed primary care patients receive adequate treatment,
and only 6% reach remission. This public health perspective helps highlight priorities that
can usefully guide both research and policy choices. For example, if one wanted to focus on
making the single system-level change that would produce the largest improvement in
attainment of remission rates, one would put efforts into improving the adequacy of
depression treatment, which could double remission rates to 12% (i.e., successfully treating
1 of 8 patients). However, the model suggests that meaningful gains can likely only be
reached by targeting multiple steps along the spectrum of depression diagnosis and care —
by improving depression recognition, treatment initiation, and treatment adequacy,
remission rates could increase from an estimated 6% to 33% (i.e., successfully treating 1 of
3 patients).
The public health perspective provides a framework for addressing the challenge of effective
depression treatment in primary care. From a policy viewpoint, the approach suggests that
comprehensive, feasible approaches, like collaborative care[27] and measurement based-
care,[64]which support care systems in initiating and maintaining high-quality evidence-
based depression treatment, could help guide primary care physicians to more proactively
and vigorously manage depression in primary care. An individual clinic might adopt as a
first step a policy of periodically screening all patients to help define the prevalence of
depression in the patient population. Alternatively, a clinic that is already comfortable with
its ability to identify and initiate treatment for depression might focus efforts on improving
the quality of treatment through a closer monitoring and management approach. Ultimately,
a combination of system-level enhancements to the identification and treatment of
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depression is likely to be necessary to meaningfully improve depression outcomes and
quality of life among primary care patients.
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Figure 2. Recognition, treatment, and remission of depression in primary care
This figure estimates, in a hypothetical population of 1,000 primary care patients, the
estimated number with depression, with clinically recognized depression, with treated
depression, with adequately treated depression, and with remitted depression.
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Figure 3. The Depression Treatment Cascade
The figure depicts, of all primary care patients with a major depressive episode in the past
year, the estimated proportion recognized clinically, receiving any treatment, receiving
adequate treatment, and achieving remission. The bars represent point estimates and the
vertical lines indicate 95% Bayesian credible intervals (Figure 4).[24]
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Figure 4. Calculation of 95% Bayesian Credible Intervals for estimates in the depression
treatment cascade
To place cumulative 95% Bayesian credible intervals (BCI)[24] around the cascade
estimates shown in Figure 3, we transformed each individual estimate (p1–p4) and BCI onto
the log scale, calculated the implied variance of each transformed estimate from its
transformed BCI, calculated the variance of each cumulative estimate on the log scale as the
sum of the variances for each component individual transformed estimate, used this variance
to calculate a 95% BCI on the log scale of the cumulative estimate, and exponentiated the
result to translate the BCI back onto the original percentage scale. For example, in the
formulas above, let p1 be the proportion of those with a depressive disorder that are
recognized clinically, and p2 be the proportion of those recognized clinically receiving any
treatment (Figure 2). Let (lb1, ub1) and (lb2, ub2) be the 95% BCIs around p1 and p2
respectively. Finally, let P2 = the proportion of those with a depressive disorder receiving
any treatment, and (LB2, UB2) be its 95% BCI.
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Figure 5. The hypothetical impact of various strategies to increase depression remission rates
The first set of bars reflects current conditions. The next four sets of bars each reflect the
impact of a single change to current conditions. In (1), improvements in screening increase
clinical recognition rates to 80%. In (2), depression treatment is initiated in 80% of those
recognized. In (3), treatment quality is improved, with 80% of those initiating treatment now
receiving best-practices treatment. In (4), new treatments are developed with 80% efficacy.
The final set of bars shows the impact of achieving (1), (2), and (3) simultaneously.
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